The 13 percent decline in procedures during the seasonally strongest first quarter casts a shadow over the year.
The AMO TECNIS Toric and Bausch + Lomb Trulign IOLs are among several noteworthy ophthalmic products to receive FDA regulatory approval in the first half of 2013.
Survey respondents reported a modest growth in premium IOL procedure share when compared with the same quarter last year.
The Catapulse uses pulsed vacuum to break up the cataract lens instead of ultrasonic energy, thereby avoiding the drawbacks of ultrasonic energy propagation.
The Alpha IMS is a subretinal implant placed beneath the fovea at the level of the photoreceptors. This contrasts with the epiretinal ARGUS II’s microchip, which is positioned atop the retina.
The Federal Trade Commission (FTC) can file an antitrust lawsuit against pharmaceutical companies that pay generic drug makers to keep their drugs off the market, the Supreme Court has ruled.
However, the court said that synthetically created DNA (known as cDNA) is patentable since it is not naturally occurring.
The proposed guidance would allow companies to apply for marketing approval of generic versions of Restasis based on laboratory tests, not on human clinical trials.
You are not currently logged in.
©2017 Market Scope
Lost your Password